Depression Treatment Trajectories and Associated Social Determinants: A Three‐Year Follow‐Up Study in 66,540 Older Adults Undergoing First‐Time Depression Treatment in Denmark DOI Creative Commons
Kazi Ishtiak‐Ahmed, Christopher Rohde, Ole Köhler‐Forsberg

и другие.

International Journal of Geriatric Psychiatry, Год журнала: 2024, Номер 39(11)

Опубликована: Ноя. 1, 2024

ABSTRACT Objective This study aimed to describe depression treatment patterns, identify unique trajectory groups using a group‐based approach, and explore associated social determinants in older adults undergoing first‐time during 3‐year follow‐up. Methods Danish register‐based cohort included all aged ≥ 65 who initiated by redeeming antidepressant prescriptions (no the last 10 years) between 2006 2015. The outcome of interest 2‐year follow‐up was treatment, assessed as redemptions psychiatric hospital contacts for depression. Latent class growth analyses were applied model trajectories 3 years. Multinomial logistic regression used analyze adjusted associations determinates group membership. Results Among 66,540 (55.2% females, mean age: 77.3 years), we identified three distinct with patterns trajectories: ‘brief‐treatment’ where individuals stopped within 6 months (33.7%); ‘gradual‐withdrawal’ (26.5%) gradually over 2 years; ‘persistent‐treatment’ continued entire years (39.8%). Females, single‐person households, residents less‐urbanized regions higher odds membership group, while age, widowhood or separation, non‐Danish ethnicities lower odds. Conclusions Three adults, indicating differential clinical courses depression—potentially influenced determinants, including sex, marital status, urban residence, ethnicity. Early patient stratification targeted interventions are crucial care adults.

Язык: Английский

Treatment-resistant depression: role of genetic factors in the perspective of clinical stratification and treatment personalisation DOI
Chiara Fabbri

Molecular Psychiatry, Год журнала: 2025, Номер unknown

Опубликована: Янв. 18, 2025

Язык: Английский

Процитировано

2

Optimizing the Treatment of Late-Life Depression DOI
Art Walaszek

American Journal of Psychiatry, Год журнала: 2024, Номер 181(1), С. 7 - 10

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

6

Exploring the correlation between cardiovascular adverse events and antidepressant use: A retrospective pharmacovigilance analysis based on the FDA Adverse Event Reporting System database DOI
Zhanzhang Wang, Haoyang Lu,

Yuandan Li

и другие.

Journal of Affective Disorders, Год журнала: 2024, Номер 367, С. 96 - 108

Опубликована: Авг. 30, 2024

Язык: Английский

Процитировано

4

Psychosocial Support in Pulmonary Rehabilitation DOI
Abebaw Mengistu Yohannes

Respiratory Care, Год журнала: 2024, Номер 69(6), С. 664 - 677

Опубликована: Апрель 30, 2024

Pulmonary rehabilitation (PR) improves exercise capacity and quality of life (QOL) while reducing dyspnea in patients with COPD. However, little is known about the efficacy PR, cognitive behavioral therapy (CBT), or antidepressant drug on psychosocial factors Knowledge gaps include which most efficacious, what barriers exist for each treatment, optimal duration intervention. Potential to patient fears potential adverse effects, apprehension misconception, stigma related depression. Both CBT PR reduce anxiety depressive symptoms short-term studies. their benefits over medium-to-long-term follow-up specifically warrant exploration. Furthermore, new emerging treatment strategies such as collaborative care model home-based telehealth coaching are promising interventions promote patient-centered adversely affecting This update critical synthesis reviews effectiveness both pharmacologic non-pharmacologic It also provides brief screening tools used assessment depression

Язык: Английский

Процитировано

3

Mind Matters in Rheumatoid Arthritis: The Rising Burden of Anxiety and Depression DOI Open Access

Nadia Sweet,

Heather Huang,

Christie M. Bartels

и другие.

The Journal of Rheumatology, Год журнала: 2025, Номер unknown, С. jrheum.2024 - 1273

Опубликована: Янв. 15, 2025

Among adults with arthritis in the United States, anxiety and depression are twice as common compared to among general population1; prevalence even higher rheumatoid (RA). Likewise, psoriatic is associated increased odds of depression,2 a systemic lupus erythematosus metaanalysis reported around 25%,3 RA, was ~37% 1 study.4

Язык: Английский

Процитировано

0

A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis DOI
Ryan D. Pittman, S. Scott Sutton, Joseph Magagnoli

и другие.

Journal of Comparative Effectiveness Research, Год журнала: 2025, Номер 14(2)

Опубликована: Янв. 27, 2025

Aim: To compare the safety and efficacy of antidepressants (AD) among older adults with major depressive disorder (MDD) by assessing treatment change, augmentation hospitalization rates. Methods: This retrospective study analyzed data from Veterans Affairs (VA) database, including 142,138 patients aged ≥60 years diagnosed MDD. Patients prescribed bupropion, citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, or venlafaxine were included. Outcomes Hazard ratios (aHRs) calculated using sertraline as reference. Results: Of patients, 39.6% required augmentation, 18.1% changed antidepressant 13.3% hospitalized. The corresponding incidence rate was 544, 124 122 events per 1000 person-years. Compared mirtazapine users had highest AD change risk (aHR 1.34, 95% CI: 1.29-1.40), while duloxetine lowest 0.87, 0.83-0.92). Duloxetine also 0.89, 0.86-0.92). Mirtazapine risks 1.15, 1.12-1.18) 1.14, 1.07-1.23). Bupropion 0.77, 0.71-0.84). Conclusion: Antidepressant choice significantly influences outcomes in demonstrated best profile posed all three outcomes. Personalized strategies are crucial to improving this population.

Язык: Английский

Процитировано

0

Ginsenoside Rg1 alleviates chronic stress-induced depression in rats by targeting Cx43-YAP axis DOI
Huiqin Wang, Ruifang Zheng, Qidi Ai

и другие.

Acta Pharmacologica Sinica, Год журнала: 2025, Номер unknown

Опубликована: Март 7, 2025

Язык: Английский

Процитировано

0

The efficacy and safety of auricular acupoint therapy on treating functional dyspepsia with insomnia: study protocol for a randomized controlled trial DOI Creative Commons
Mouquan Shen, Qingqing Lou, Shan Liu

и другие.

Frontiers in Medicine, Год журнала: 2025, Номер 12

Опубликована: Март 12, 2025

Background Functional dyspepsia (FD) is a prevalent health issue currently lacking optimal treatment options, with its global incidence rate increasing in recent years. Clinical studies have recently focused on the application of auriculotherapy functional gastrointestinal disorders that are accompanied by negative emotions. However, few randomized controlled trials investigated use for FD patients insomnia, leaving therapeutic efficacy and safety largely undefined. This study aims to evaluate clinical treating insomnia. Methods analysis single-center, trial involving 80 Using central randomization system, subjects randomly assigned auricular acupressure group or sham at 1:1 ratio, targeting concha region earlobe region. The primary outcome response 2 weeks, secondary outcomes include 8 sleep data assessed actigraphy, modified Dyspepsia Symptom Diary, short form-Nepean Index, Self-rated Anxiety Scale, Depression High Arousal Heart Rate Variability. Efficacy results will be evaluated baseline weeks after treatment. Adverse events monitored throughout observation period. Discussion this anticipated validate improving symptoms as well reducing emotional states. registration ClinicalTrials.gov , NCT06466044. Registered 14th May 2024, https://register.clinicaltrials.gov .

Язык: Английский

Процитировано

0

Contribution of depression and cardiometabolic diseases and the role of depression treatment in survival and functioning in older adults DOI Creative Commons
Najmeh Davoodian, Malcolm Forbes, Michael Berk

и другие.

EClinicalMedicine, Год журнала: 2025, Номер 82, С. 103182 - 103182

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Sociodemographics and clinical factors associated with depression treatment outcomes in 65,741 first-time users of selective serotonin reuptake inhibitors: A Danish cohort study in older adults DOI Creative Commons
Kazi Ishtiak‐Ahmed, Kaj Sparle Christensen, Erik Lykke Mortensen

и другие.

Journal of Affective Disorders, Год журнала: 2024, Номер 367, С. 244 - 254

Опубликована: Сен. 3, 2024

To investigate a wide range of sociodemographic and clinical factors associated with treatment outcomes in older adults who initiated an SSRI for depression real-world setting.

Язык: Английский

Процитировано

2